Bioorthogonal Prodrug–Antibody Conjugates for On-Target and On-Demand Chemotherapy
Authors:
Open Access
- 1 June 2019
- journal article
- research article
- Published by Chinese Chemical Society in CCS Chemistry
- Vol. 1 (2) , 226-236
Abstract
Current antibody–drug conjugates (ADCs) suffer from low tissue penetration and significant side effects, largely due to the permanent linkage and/or premature release of cytotoxic payloads. Herein,...Keywords
This publication has 42 references indexed in Scilit:
- A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer TherapyAngewandte Chemie, 2011
- Prodrugs: design and clinical applicationsNature Reviews Drug Discovery, 2008
- Ruthenium‐Induced Allylcarbamate Cleavage in Living CellsAngewandte Chemie International Edition, 2006
- Drug penetration in solid tumoursNature Reviews Cancer, 2006
- Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug CarriersJNCI: Journal of the National Cancer Institute, 2006
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Ligand-targeted therapeutics in anticancer therapyNature Reviews Cancer, 2002
- Redox Pathway Leading to the Alkylation of DNA by the Anthracycline, Antitumor Drugs Adriamycin and DaunomycinJournal of Medicinal Chemistry, 1997
- Comparative Adverse Effect Profiles of Platinum DrugsDrug Safety, 1995
- (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicinBioconjugate Chemistry, 1993